<DOC>
	<DOCNO>NCT00002250</DOCNO>
	<brief_summary>To test effectiveness recombinant human CD4 Immunoglobulin G ( CD4-IgG ) treatment HIV-associated immune thrombocytopenic purpura patient level HIV infection .</brief_summary>
	<brief_title>A Phase I Study Recombinant Human CD4 Immunoglobulin G ( rCD4-lgG ) Patients With HIV-Associated Immune Thrombocytopenic Purpura</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>CD4 Immunoadhesins</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Dapsone constant dose level prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Zidovudine ( AZT ) constant dose 12 week treatment , except AZTrelated toxicity observe . Patients must follow : HIV seropositive ( asymptomatic , AIDSrelated complex , AIDS ) . HIVassociated immune thrombocytopenic purpura . The ability sign write informed consent form , must obtain prior treatment . A willingness abstain experimental therapy HIV infection entire study period . Patients currently zidovudine exclude . However , zidovudine dose level must remain constant 4 week prior entry 12 week treatment , except zidovudine relate toxicity observe . A life expectancy least 3 month . Prior Medication : Allowed : Dapsone constant dose 2 week prior study entry . Zidovudine constant dose 4 week prior study entry . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active serious opportunistic infection ( exclude positive block culture Mycobacterium avium complex Cytomegalovirus ) . Malignancies Kaposi 's sarcoma . Tumorassociated edema . Visceral Kaposi 's sarcoma . Significant neurologic , cardiac , liver disease . Concurrent Medication : Excluded : Ganciclovir ( DHPG ) . Pyrimethamine . Clindamycin . Sulfadiazine . Folinic acid . Prednisone . Intravenous gamma globulin . Intravenous acyclovir . Interferon . Systemic corticosteroid . Nonsteroidal antiinflammatory drug ( NSAIDs ) . Known immunomodulatory agent . Dideoxycytosine . Dideoxyinosine . Nucleoside analog ( exception zidovudine topical acyclovir ) . Any experimental therapy . Patients follow exclude : Active serious opportunistic infection ( exclude positive block culture Mycobacterium avium complex Cytomegalovirus ) . Malignancies Kaposi 's sarcoma . Kaposi 's sarcoma require therapy . Tumorassociated edema . Visceral Kaposi 's sarcoma . Significant neurologic , cardiac , liver disease . Conditions require exclude concomitant medication . Herpes virus infection require intravenous acyclovir . Prior Medication : Excluded minimum 4 week prior study entry : Chemotherapy . Immunomodulatory agent . Any experimental therapy . Prior Treatment : Excluded minimum 4 week prior study entry : Radiation therapy . Any experimental therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1991</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>IgG</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Antigens , CD4</keyword>
</DOC>